Literature DB >> 24186934

Matrix metalloproteinase-9: Many shades of function in cardiovascular disease.

Andriy Yabluchanskiy1, Yonggang Ma, Rugmani Padmanabhan Iyer, Michael E Hall, Merry L Lindsey.   

Abstract

Matrix metalloproteinase (MMP)-9, one of the most widely investigated MMPs, regulates pathological remodeling processes that involve inflammation and fibrosis in cardiovascular disease. MMP-9 directly degrades extracellular matrix (ECM) proteins and activates cytokines and chemokines to regulate tissue remodeling. MMP-9 deletion or inhibition has proven overall beneficial in multiple animal models of cardiovascular disease. As such, MMP-9 expression and activity is a common end point measured. MMP-9 cell-specific overexpression, however, has also proven beneficial and highlights the fact that little information is available on the underlying mechanisms of MMP-9 function. In this review, we summarize our current understanding of MMP-9 physiology, including structure, regulation, activation, and downstream effects of increased MMP-9. We discuss MMP-9 roles during inflammation and fibrosis in cardiovascular disease. By concentrating on the substrates of MMP-9 and their roles in cardiovascular disease, we explore the overall function and discuss future directions on the translational potential of MMP-9 based therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24186934      PMCID: PMC3858212          DOI: 10.1152/physiol.00029.2013

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN: 1548-9221


  144 in total

1.  Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs.

Authors:  T Etoh; C Joffs; A M Deschamps; J Davis; K Dowdy; J Hendrick; S Baicu; R Mukherjee; M Manhaini; F G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-09       Impact factor: 4.733

Review 2.  The AP-1 site and MMP gene regulation: what is all the fuss about?

Authors:  U Benbow; C E Brinckerhoff
Journal:  Matrix Biol       Date:  1997-03       Impact factor: 11.583

3.  Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.

Authors:  S Hinan Ahmed; Leslie L Clark; Weems R Pennington; Carson S Webb; D Dirk Bonnema; Amy H Leonardi; Catherine D McClure; Francis G Spinale; Michael R Zile
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

4.  Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.

Authors:  Satoshi Yasuda; Shunichi Miyazaki; Hideyuki Kinoshita; Noritoshi Nagaya; Munetake Kanda; Yoichi Goto; Hiroshi Nonogi
Journal:  Clin Sci (Lond)       Date:  2007-01       Impact factor: 6.124

5.  Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.

Authors:  G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

6.  Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals.

Authors:  Carmel M McEniery; Kevin M O'Shaughnessy; Patrick Harnett; Asif Arshad; Sharon Wallace; Kaisa Maki-Petaja; Barry McDonnell; Mike J Ashby; John Brown; John R Cockcroft; Ian B Wilkinson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-05-18       Impact factor: 8.311

7.  Intramyocardial injection of heart tissue-derived extracellular matrix improves postinfarction cardiac function in rats.

Authors:  Wangde Dai; Paul Gerczuk; Yuanyuan Zhang; Leona Smith; Oleg Kopyov; Gregory L Kay; Aarne J Jyrala; Robert A Kloner
Journal:  J Cardiovasc Pharmacol Ther       Date:  2013-01-22       Impact factor: 2.457

8.  Platelet-activating factor overturns the transcriptional repressor disposition of Sp1 in the expression of MMP-9 in human corneal epithelial cells.

Authors:  Faramarz Taheri; Haydee E P Bazan
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-05       Impact factor: 4.799

9.  Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension.

Authors:  S Zhou; J Feely; J P Spiers; A Mahmud
Journal:  J Hum Hypertens       Date:  2007-06-21       Impact factor: 3.012

10.  Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.

Authors:  Jing Tan; Qi Hua; Xiurong Xing; Jing Wen; Rongkun Liu; Zheng Yang
Journal:  Hypertens Res       Date:  2007-10       Impact factor: 3.872

View more
  161 in total

1.  Myocardial Infarction Superimposed on Aging: MMP-9 Deletion Promotes M2 Macrophage Polarization.

Authors:  Andriy Yabluchanskiy; Yonggang Ma; Kristine Y DeLeon-Pennell; Raffaele Altara; Ganesh V Halade; Andrew P Voorhees; Nguyen T Nguyen; Yu-Fang Jin; Michael D Winniford; Michael E Hall; Hai-Chao Han; Merry L Lindsey
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-04-15       Impact factor: 6.053

Review 2.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

3.  Tissue Inhibitor of Metalloproteinase-1: Actions beyond Matrix Metalloproteinase Inhibition.

Authors:  Merry L Lindsey; Andriy Yabluchanskiy; Yonggang Ma
Journal:  Cardiology       Date:  2015-08-01       Impact factor: 1.869

4.  Endothelial MMP-9 drives the inflammatory response in abdominal aortic aneurysm (AAA).

Authors:  Martina Ramella; Francesca Boccafoschi; Kevin Bellofatto; Antonia Follenzi; Luca Fusaro; Renzo Boldorini; Francesco Casella; Carla Porta; Piergiorgio Settembrini; Mario Cannas
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

5.  Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain.

Authors:  Chun Gu; Fang Wang; Zhihui Hou; Bin Lv; Yang Wang; Xiangfeng Cong; Xi Chen
Journal:  Heart Vessels       Date:  2017-07-19       Impact factor: 2.037

Review 6.  Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling.

Authors:  Merry L Lindsey
Journal:  Nat Rev Cardiol       Date:  2018-08       Impact factor: 32.419

7.  Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A.

Authors:  Lucy Lin; Lewis D Turner; Peter Šilhár; Sabine Pellett; Eric A Johnson; Kim D Janda
Journal:  RSC Med Chem       Date:  2020-11-12

8.  Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet.

Authors:  Guanghong Jia; Javad Habibi; Brian P Bostick; Lixin Ma; Vincent G DeMarco; Annayya R Aroor; Melvin R Hayden; Adam T Whaley-Connell; James R Sowers
Journal:  Hypertension       Date:  2014-12-08       Impact factor: 10.190

Review 9.  Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease.

Authors:  Anthony J Donato; Daniel R Machin; Lisa A Lesniewski
Journal:  Circ Res       Date:  2018-09-14       Impact factor: 17.367

Review 10.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.